Amarin Corp Ads (AMRN)
$4.01
0.16 (3.84%)
AMRN Stock Quote Delayed 30 Minutes
Previous Close
$4.01
Market Cap
1.18B
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
8.70M
Day's Range
3.92 - 4.11
52-Week Range
3.91 - 26.12
Dividend & Yield
N/A (N/A)
AMRN Stock Predictions, Articles, and Amarin Corp Ads News
Amarin’s Vascepa Is a Great Story Filled With Too Many Unknowns
The biggest unknown weighing on Amarin stock is how long the decision to take Vascepa will be up to patients, rather than experts.
Bears Are Now in Control of Amarin Stock, But Not for Long
Bears are in control of Amarin stock, and selling pressure has driven the price down. But Vascepa will drive huge success for Amarin in 2020.
Does the Recent Amarin Stock Pullback Put Shares in the Buy Category?
Amarin stock is struggling, and that's been the case even before the stock market pulled back. Here's how AMRN looks now.
Consider Adding Amarin to Your Portfolio as Its Competition Falters
Investors should feel confident adding Amarin stock to their portfolios, especially because it has the government on its side.
Amarin Stock Will Deliver More Upside for Patient Investors
As Vascepa's competition dwindles and the drug gains market share, AMRN stock could be in for some significant upside in 2020.
Amarin Stock Projections Are Based on Hype and Hope
Amarin stock has some potential, but there are also many risks involved. Therefore, it doesn’t hurt to wait if you really want to buy these shares.
Amarin Stock is Still Fully Valued Despite All the Good News
AMRN stock is likely fairly priced -- possibly even overpriced -- right now. It might take more time before analysts and the company actually raise their revenue and cash flow estimates based on patient uptake of Vascepa.
It’s Time to Go Long Amarin Stock After Recent Headlines
AstraZeneca out of the way. Plus, some key technical resistance is also dismantled, so it’s time to go long AMRN stock today.
Why Amarin Stock Is Poised for a Healthy 2020
During the past year, Amarin stock has been a laggard. But this could change in 2020 with the company's new drug poised for long-term growth.
After FDA Approval, Amarin Stock Is Stuck in Worrisome Trading
Amarin stock has faded in recent weeks despite a spate of good news. That response suggests AMRN shares may have further to fall.
AstraZeneca’s Loss is Amarin’s Big Gain This Year
AstraZeneca is stopping a large clinical study of its fish-oil-derived heart drug, Epanova. That’s good news for Amarin and Amarin stock.
Amarin Stock Bouncing Back After Revised Results and 2020 Guidance
Amarin stock is set for growth with Vascepa approval and sales outlook for 2020 predicting revenue will eventually hit billions of dollars
A Recent FDA Approval Will Be Huge in Moving Amarin Stock
FDA approval of Vascepa in use for cardiovascular events just widened Amarin’s revenue potential. Amarin stock should have a banner 2020.
Is Amarin Stock a Top Pick for 2020?
Amarin stock has been on fire in 2019, but the reaction to its latest news was discouraging. Is that a buying opportunity or a warning sign?
Amarin Stock Primed for New Highs
Amarin stock is beating the indices and its sector etf's for a reason. Its chart suggests that there is an exciting move brewing.
Amarin Risks Getting Exposed as a Paper Tiger
Pharmaceutical companies are always difficult investment propositions, and Amarin shares proved why with its perhaps unjustifiably hyped drug Vascepa.
Vascepa’s Future Looks Rosy, But It Could Still Be Fishy for Amarin Stock
Amarin is doubling its sales force for Vascepa, a cholesterol-fighting drug, as potential competitors await results from their own trials.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
D
